The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Advancements in peripheral T cell lymphoma
Stefano Luminari, MD, University of Modena and Reggio Emilia, Emilia-Romagna, Italy analyzes new trends within peripheral T cell lymphoma (PTCL). Assessing the cell of origin and cell type has improved diagnosis of PTCL, where treatments for patients can be subsequently optimized. Certain subtypes respond better particular treatments; neoplastic lymphomas responds better to brentuximab vedotin whereas epigenetic modifiers are better suited for T follicular helper cell lymphoma. More cooperation is required to gather sufficient data to develop novel therapies. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
